Research programme: hepcidin peptide mimetics - Merganser Biotech / University of California at Los Angeles

Drug Profile

Research programme: hepcidin peptide mimetics - Merganser Biotech / University of California at Los Angeles

Alternative Names: Hepcidin mimetic peptides; M 009; Minihepcidin peptides; Minihepcidins

Latest Information Update: 21 Feb 2015

Price : $50

At a glance

  • Originator University of California at Los Angeles
  • Developer Merganser Biotech; University of California at Los Angeles; Weill Cornell Medical College
  • Class Peptides
  • Mechanism of Action Hepcidin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Beta-thalassaemia; Haemochromatosis; Iron overload; Polycythaemia vera

Most Recent Events

  • 20 Feb 2015 Preclinical trials in Beta-thalassaemia in USA (Parenteral)
  • 20 Feb 2015 Preclinical trials in Haemochromatosis in USA (Parenteral)
  • 20 Feb 2015 Preclinical trials in Iron overload in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top